PolyPid Ltd. (PYPD)
NASDAQ: PYPD · Real-Time Price · USD
3.220
-0.240 (-6.94%)
Dec 20, 2024, 4:00 PM EST - Market closed
PolyPid Employees
As of December 31, 2023, PolyPid had 62 total employees, including 59 full-time and 3 part-time employees. The number of employees increased by 2 or 3.33% compared to the previous year.
Employees
62
Change (1Y)
2
Growth (1Y)
3.33%
Revenue / Employee
n/a
Profits / Employee
-$433,194
Market Cap
21.91M
Employees Chart
Related Stocks
| Company Name | Employees |
|---|---|
| Co-Diagnostics | 155 |
| Vivos Therapeutics | 123 |
| NKGen Biotech | 63 |
| Cara Therapeutics | 55 |
| NeurAxis | 19 |
| NeuroOne Medical Technologies | 16 |
| Akari Therapeutics, | 12 |
| Cocrystal Pharma | 12 |
PYPD News
- 10 days ago - PolyPid Announces Research and Development Collaboration with ImmunoGenesis Leveraging PLEX Technology to Enhance Cancer Immunotherapy - GlobeNewsWire
- 22 days ago - PolyPid Announces Receipt of Nasdaq Notification of Minimum Stockholders' Equity Non-Compliance - GlobeNewsWire
- 5 weeks ago - PolyPid Ltd. (PYPD) Q3 2024 Earnings Call Transcript - Seeking Alpha
- 6 weeks ago - PolyPid to Participate in the Craig-Hallum 15th Annual Alpha Select Conference - GlobeNewsWire
- 7 weeks ago - PolyPid to Report Third Quarter 2024 Financial Results and Operational Highlights on November 13, 2024 - GlobeNewsWire
- 2 months ago - PolyPid Announces Publication in International Journal of Surgery Highlighting Results of Phase 3 SHIELD I Trial of D-PLEX₁₀₀ in Prevention of Surgical Site Infections in Abdominal Colorectal Surgery - GlobeNewsWire
- 2 months ago - PolyPid Announces Last Patient In for Planned Unblinded Interim Analysis in the Ongoing SHIELD II Phase 3 Trial Evaluating D-PLEX₁₀₀ for the Prevention of Abdominal Colorectal Surgical Site Infections - GlobeNewsWire
- 3 months ago - PolyPid to Participate in Three Upcoming Fall Investor Conferences - GlobeNewsWire